MIRM
Mirum Pharmaceuticals, Inc.
Biotechnology
Market Cap$5.17B
5Y Perf.+510.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MIRM vs FOLD vs RARE vs SRPT
Revenue, margins, valuation, and 5-year total return — side by side.
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
SRPT
Sarepta Therapeutics, Inc.
Biotechnology
Market Cap$2.18B
5Y Perf.-86.3%
MIRM vs FOLD vs RARE vs SRPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MIRM | FOLD | RARE | SRPT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5.17B | $4.55B | $2.57B | $2.18B |
| Revenue (TTM) | $410M | $634M | $669M | $2.18B |
| Net Income (TTM) | $-799M | $-27M | $-609M | $65M |
| Gross Margin | -103.2% | 87.9% | 83.6% | 34.4% |
| Operating Margin | -194.4% | 5.2% | -83.9% | -1.9% |
| Forward P/E | — | 40.6x | — | 6.9x |
| Total Debt | $319M | $483M | $1.28B | $1.04B |
| Cash & Equiv. | $297M | $214M | $434M | $801M |
MIRM vs FOLD vs RARE vs SRPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MIRM
FOLD
RARE
SRPT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mirum Pharmaceutica… (MIRM) | 100 | 610.9 | +510.9% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
| Sarepta Therapeutic… (SRPT) | 100 | 13.7 | -86.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MIRM vs FOLD vs RARE vs SRPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRPT leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Mirum Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. FOLD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
MIRM
Mirum Pharmaceuticals, Inc.
The Growth Play
MIRM is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 54.7%, EPS growth 74.6%, 3Y rev CAGR 89.1%
- 6.8% 10Y total return vs FOLD's 119.2%
- 54.7% revenue growth vs SRPT's 15.6%
- +149.7% vs SRPT's -43.4%
Best for: growth exposure and long-term compounding
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.63
- Lower volatility, beta 0.63, current ratio 2.84x
- Beta 0.63, current ratio 2.84x
- Beta 0.63 vs SRPT's 2.02
Best for: income & stability and sleep-well-at-night
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
SRPT
Sarepta Therapeutics, Inc.
The Value Play
SRPT carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 3.0% margin vs MIRM's -195.0%
- 1.9% ROA vs MIRM's -98.5%, ROIC -31.4% vs -5.0%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MIRM | 54.7% revenue growth vs SRPT's 15.6% |
| Value | SRPT | Better valuation composite |
| Quality / Margins | SRPT | 3.0% margin vs MIRM's -195.0% |
| Stability / Safety | FOLD | Beta 0.63 vs SRPT's 2.02 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | MIRM | +149.7% vs SRPT's -43.4% |
| Efficiency (ROA) | SRPT | 1.9% ROA vs MIRM's -98.5%, ROIC -31.4% vs -5.0% |
MIRM vs FOLD vs RARE vs SRPT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
MIRM vs FOLD vs RARE vs SRPT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMIRMLAGGINGRARE
Who Leads Where
SRPT leads in 1 of 6 categories
MIRM leads 1 • FOLD leads 1 • RARE leads 0 • 2 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
SRPTSarepta Therapeutics,…
1leads
FOLDAmicus Therapeutics, …
1leads
MIRMMirum Pharmaceuticals…
1leads
6 Total Categories
CATEGORYLEADERvs FOLDvs SRPTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SRPT3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MIRM6/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — FOLD and SRPT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRPT is the larger business by revenue, generating $2.2B annually — 5.3x MIRM's $410M. SRPT is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to MIRM's -195.0%. On growth, FOLD holds the edge at +23.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $410M | $634M | $669M | $2.2B |
| EBITDAEarnings before interest/tax | -$778M | $40M | -$536M | -$6M |
| Net IncomeAfter-tax profit | -$799M | -$27M | -$609M | $65M |
| Free Cash FlowCash after capex | -$173M | $30M | -$487M | $107M |
| Gross MarginGross profit ÷ Revenue | -103.2% | +87.9% | +83.6% | +34.4% |
| Operating MarginEBIT ÷ Revenue | -194.4% | +5.2% | -83.9% | -1.9% |
| Net MarginNet income ÷ Revenue | -195.0% | -4.3% | -91.0% | +3.0% |
| FCF MarginFCF ÷ Revenue | -42.1% | +4.7% | -72.8% | +4.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +23.7% | -2.4% | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -43.8% | -89.0% | -17.2% | +162.6% |
Evenly matched — FOLD and SRPT each lead in 3 of 6 comparable metrics.
Valuation Metrics
SRPT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, FOLD's 114.9x EV/EBITDA is more attractive than MIRM's 2461.9x.
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Market CapShares × price | $5.2B | $4.5B | $2.6B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $4.8B | $3.4B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -219.00x | -164.85x | -4.48x | -2.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 40.62x | — | 6.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 2461.91x | 114.88x | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.91x | 7.17x | 3.82x | 0.99x |
| Price / BookPrice ÷ Book value/share | 16.42x | 16.29x | — | 1.91x |
| Price / FCFMarket cap ÷ FCF | 94.16x | 152.43x | — | — |
SRPT leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — MIRM and FOLD and SRPT each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
SRPT delivers a 4.9% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-6 for RARE. SRPT carries lower financial leverage with a 0.91x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), MIRM scores 6/9 vs SRPT's 4/9, reflecting solid financial health.
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.9% | -12.0% | -6.1% | +4.9% |
| ROA (TTM)Return on assets | -98.5% | -3.2% | -45.8% | +1.9% |
| ROICReturn on invested capital | -5.0% | +5.3% | -89.4% | -31.4% |
| ROCEReturn on capital employed | -3.7% | +5.1% | -46.4% | -24.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 4 |
| Debt / EquityFinancial leverage | 1.02x | 1.76x | — | 0.91x |
| Net DebtTotal debt minus cash | $23M | $269M | $842M | $238M |
| Cash & Equiv.Liquid assets | $297M | $214M | $434M | $801M |
| Total DebtShort + long-term debt | $319M | $483M | $1.3B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | -0.03x | 1.00x | -14.49x | -14.00x |
Evenly matched — MIRM and FOLD and SRPT each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
MIRM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MIRM five years ago would be worth $55,131 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, MIRM leads with a +149.7% total return vs SRPT's -43.4%. The 3-year compound annual growth rate (CAGR) favors MIRM at 57.5% vs SRPT's -45.3% — a key indicator of consistent wealth creation.
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.8% | +1.5% | +10.7% | -2.4% |
| 1-Year ReturnPast 12 months | +149.7% | +137.9% | -21.8% | -43.4% |
| 3-Year ReturnCumulative with dividends | +290.5% | +19.0% | -44.5% | -83.6% |
| 5-Year ReturnCumulative with dividends | +451.3% | +48.6% | -77.2% | -72.1% |
| 10-Year ReturnCumulative with dividends | +679.2% | +119.2% | -59.4% | +18.0% |
| CAGR (3Y)Annualised 3-year return | +57.5% | +6.0% | -17.8% | -45.3% |
MIRM leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than SRPT's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs SRPT's 47.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 0.63x | 1.42x | 2.02x |
| 52-Week HighHighest price in past year | $112.00 | $14.50 | $42.37 | $44.14 |
| 52-Week LowLowest price in past year | $40.00 | $5.51 | $18.29 | $10.42 |
| % of 52W HighCurrent price vs 52-week peak | +91.9% | +99.9% | +61.7% | +47.1% |
| RSI (14)Momentum oscillator 0–100 | 73.5 | 72.2 | 66.6 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 833K | 3.0M | 1.8M | 3.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MIRM as "Buy", FOLD as "Buy", RARE as "Buy", SRPT as "Buy". Consensus price targets imply 97.1% upside for RARE (target: $52) vs 0.1% for FOLD (target: $15).
| Metric | MIRMMirum Pharmaceuti… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | SRPTSarepta Therapeut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $120.40 | $14.50 | $51.50 | $24.63 |
| # AnalystsCovering analysts | 18 | 24 | 33 | 54 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
SRPT leads in 1 of 6 categories (Valuation Metrics). MIRM leads in 1 (Total Returns). 2 tied.
Best OverallMirum Pharmaceuticals, Inc. (MIRM)Leads 1 of 6 categories
Loading custom metrics...
MIRM vs FOLD vs RARE vs SRPT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is MIRM or FOLD or RARE or SRPT a better buy right now?
For growth investors, Mirum Pharmaceuticals, Inc.
(MIRM) is the stronger pick with 54. 7% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Analysts rate Mirum Pharmaceuticals, Inc. (MIRM) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MIRM or FOLD or RARE or SRPT?
Over the past 5 years, Mirum Pharmaceuticals, Inc.
(MIRM) delivered a total return of +451. 3%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: MIRM returned +679. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MIRM or FOLD or RARE or SRPT?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 221% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Sarepta Therapeutics, Inc. (SRPT) carries a lower debt/equity ratio of 91% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MIRM or FOLD or RARE or SRPT?
By revenue growth (latest reported year), Mirum Pharmaceuticals, Inc.
(MIRM) is pulling ahead at 54. 7% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Mirum Pharmaceuticals, Inc. grew EPS 74. 6% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, MIRM leads at 89. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MIRM or FOLD or RARE or SRPT?
Amicus Therapeutics, Inc.
(FOLD) is the more profitable company, earning -4. 3% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MIRM or FOLD or RARE or SRPT more undervalued right now?
On forward earnings alone, Sarepta Therapeutics, Inc.
(SRPT) trades at 6. 9x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 33. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 97. 1% to $51. 50.
07Which pays a better dividend — MIRM or FOLD or RARE or SRPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is MIRM or FOLD or RARE or SRPT better for a retirement portfolio?
For long-horizon retirement investors, Mirum Pharmaceuticals, Inc.
(MIRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +679. 2% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MIRM: +679. 2%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MIRM and FOLD and RARE and SRPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(MIRM: -100.0% · FOLD: 23.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.